Global Non Hodgkin Lymphoma Market
Market Size in USD Billion
CAGR :
% 
USD
8.33 Billion
USD
16.00 Billion
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 8.33 Billion |
 Market Size (Forecast Year) |
USD 16.00 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Non Hodgkin Lymphoma Market, By Type (B-Cell Lymphomas, T-Cell Lymphoma), Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Non Hodgkin Lymphoma Market Analysis and Size
The non hodgkin lymphoma market is expected to witness significant growth during the forecast period. The global paediatric hodgkin lymphoma market is majorly driven by high prevalence of non-hodgkin lymphoma, increases in number of promising pipeline drugs, high diagnostics rate and vulnerable paediatric population. Multiple treatment landscape and family history of ovarian cancer are considered positive indicators for the demand for novel ovarian cancer drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the non hodgkin lymphoma market in the forecast period 2022-2029. The expected CAGR of global non hodgkin lymphoma market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 8.33 billion in 2021, and it would grow upto USD 16 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Non-Hodgkin lymphoma is a serious and life-threatening cancer that belongs to the group of lymphomas that is developed from the lymph nodes which are the part of the immune system. Lymph nodes has key role in fighting against the infections. In the non-hodgkin lymphoma, the lymph nodes become cancerous which could affect throughout the body. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Non Hodgkin Lymphoma Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (B-Cell Lymphomas, T-Cell Lymphoma), Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Seagen, Inc (U.S.), ONO Pharmaceutical Co., Ltd. (Japan) |
|
Market Opportunities |
|
Global Non Hodgkin Lymphoma Market Dynamics
Drivers
- Increasing Investments by Market Players
Several growth strategies such as novel product launches aid in leading market players gain a competitive edge over the other players, in the upcoming years. Collaboration between major market players and smaller players can help increase their revenue shares. The smaller market leaders will acquire investments from private investors, which in turn could help them in their long-term growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Non-Hodgkin Lymphoma
According to the American Cancer Society, non-Hodgkin lymphoma is estimated to be around 80,470. The highest rates are seen in the age group between 80 to 84 years for females and the 85 to 89 years for males. Some of these cancers are very aggressive. The need for better clinical outcomes are required more and more to treat the patients effectively. Thus, it boosts the market growth.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing on launching the drugs that are beneficial for the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global non hodgkin lymphoma market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth. Many a times, due to lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return hampers their health. Thus, this is an important restrain that needs to be taken care of.
This non hodgkin lymphoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non hodgkin lymphoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Non Hodgkin Lymphoma Market Scope
The non hodgkin lymphoma market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- B-Cell Lymphomas
- T-Cell Lymphoma
Treatment Type
- Chemotherapy
- Targeted Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Non Hodgkin Lymphoma Market Regional Analysis/Insights
The non hodgkin lymphoma market is analysed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the non hodgkin lymphoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the well-developed regulatory framework and high demand of diseases specific treatment.
Asia-Pacific dominates the market due to the rise in number of generic manufacturers in this region as well as increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Non Hodgkin Lymphoma Market Share Analysis
The non hodgkin lymphoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to non hodgkin lymphoma market.
Key players operating in the non hodgkin lymphoma market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NON-HODGKIN LYMPHOMA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL NON-HODGKIN LYMPHOMA MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 REGULATORY FRAMEWORK
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
10 GLOBAL NON-HODGKIN LYMPHOMA MARKET, BY TYPE
11 (MARKET VALUE , VOLUME AND AVERAGE SELLING PRICE WILL BE PROVIDED FOR ALL THE SEGMENTS)
11.1 OVERVIEW
11.2 B- CELL LYMPHOMAS
11.2.1 BY TREATMENT
11.2.1.1. CHEMOTHERAPY
11.2.1.1.1. ALKYLATING AGENTS
11.2.1.1.1.1 CYCLOPHOSPHAMIDE
11.2.1.1.1.1.1. MARKET VALEU (USD MN)
11.2.1.1.1.1.2. MARKET VOLUME (SU)
11.2.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.2 CHLORAMBUCIL
11.2.1.1.1.3 BENDAMUSTINE
11.2.1.1.1.4 IFOSFAMIDE
11.2.1.1.2. CORTICOSTEROIDS
11.2.1.1.2.1 PREDNISONE
11.2.1.1.2.2 DEXAMETHASONE
11.2.1.1.3. PLATINUM DRUGS
11.2.1.1.3.1 CISPLATIN
11.2.1.1.3.2 CARBOPLATIN
11.2.1.1.3.3 OXALIPLATIN
11.2.1.1.4. ANTI-METABOLITES
11.2.1.1.4.1 CYTARABINE (ARA-C)
11.2.1.1.4.2 GEMCITABINE
11.2.1.1.4.3 METHOTREXATE
11.2.1.1.4.4 PRALATREXATE
11.2.1.1.4.5 OTHERS
11.2.1.1.5. ANTHRACYCLINES
11.2.1.1.5.1 DOXORUBICIN
11.2.1.1.5.2 LIPOSOMAL DOXORUBICIN
11.2.1.1.6. OTHERS
11.2.1.1.6.1 VINCRISTINE
11.2.1.1.6.2 BLEOMYCIN
11.2.1.1.6.3 MITOXABNTRONE
11.2.1.1.6.4 ETOPOSIDE
11.2.2 TARGETED DRUG THERAPY
11.2.2.1. IBRUTINIB (IMBRUVICA)
11.2.2.2. BORTEZOMIB (VELCADE)
11.2.2.3. VENETOCLAX (VENCLEXTA)
11.2.2.4. ACALABRUTINIB (CALQUENCE)
11.2.2.5. OTHERS
11.2.3 IMMUNOTHERAPY
11.2.3.1. MONOCLONAL ANTIBODIES
11.2.3.1.1. RITUXIMAB
11.2.3.1.2. OBINUTUZUMAB
11.2.3.1.3. OFATUMUMAB (ARZERRA)
11.2.3.1.4. IBRITUMOMAB TIUXETAN (ZELAVIN)
11.2.3.1.5. TAFASTIMAB (MONJUVI)
11.2.3.1.6. LONCASTUXIMAB TESIRINE (ZYLONTA)
11.2.3.1.7. ALEMTUZUMAB
11.2.3.1.8. BRENTUXIMAB VEDOTIN (ADCETRIS)
11.2.3.1.9. POLATUZUMAB VEDOTIN (POLIVY)
11.2.3.1.10. OTHERS
11.2.3.2. IMMUNE CHECKPOINT INHIBITORS
11.2.3.2.1. PEMBROLIZUMAB (KEYTRUDA)
11.2.3.2.2. OTHERS
11.2.3.3. IMMUNOMODULATING DRUGS
11.2.3.3.1. THALIDOMIDE
11.2.3.3.2. LENALIDOMIDE
11.2.3.4. CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
11.2.3.4.1. AXICABTAGENE CLIOLEUCEL (YESCARTA)
11.2.3.4.2. TISAGENLECLEUCEL (KYMRIAH)
11.2.3.4.3. LISCOBTAGENE MARALEUCEL (BREYANZI)
11.2.3.4.4. BREXUCABTAGENE AUTOLEUCEL (TECRTUS)
11.2.4 BY ROUTE OF ADMINISTRATION
11.2.4.1. ORAL
11.2.4.2. PARENTERAL
11.2.4.3. INTRATHECAL
11.2.5 BY DISEASE TYPE
11.2.5.1. DIFFUSE LARGE B-CELL LYMPHOMA
11.2.5.2. FOLLICULAR LYMPHOMA
11.2.5.3. MANTLE CELL LYMPHOMA
11.2.5.4. BURKITT LYMPHOMA
11.3 T-CELL LYMPHOMAS
11.3.1 BY TYPE
11.3.1.1. T-LYMPHOBLASTIC LYMPHOMA/LEUKEMIA
11.3.1.2. PERIPHERAL T-CELL LYMPHOMA
11.3.1.2.1. CUTANEOUS T-CELL LYMPHOMA
11.3.1.2.2. ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
11.3.1.2.3. ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
11.3.1.2.4. ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
11.3.2 BY TREATMENT
11.3.2.1. CHEMOTHERAPY
11.3.2.1.1. ALKYLATING AGENTS
11.3.2.1.1.1 CYCLOPHOSPHAMIDE
11.3.2.1.1.2 CHLORAMBUCIL
11.3.2.1.1.3 BENDAMUSTINE
11.3.2.1.1.4 IFOSFAMIDE
11.3.2.1.2. CORTICOSTEROIDS
11.3.2.1.2.1 PREDNISONE
11.3.2.1.2.2 DEXAMETHASONE
11.3.2.1.3. PLATINUM DRUGS
11.3.2.1.3.1 CISPLATIN
11.3.2.1.3.2 CARBOPLATIN
11.3.2.1.3.3 OXALIPLATIN
11.3.2.1.4. ANTI-METABOLITES
11.3.2.1.4.1 CYTARABINE (ARA-C)
11.3.2.1.4.2 GEMCITABINE
11.3.2.1.4.3 METHOTREXATE
11.3.2.1.4.4 PRALATREXATE
11.3.2.1.4.5 OTHERS
11.3.2.1.5. ANTHRACYCLINES
11.3.2.1.5.1 DOXORUBICIN
11.3.2.1.5.2 LIPOSOMAL DOXORUBICIN
11.3.2.1.6. OTHERS
11.3.2.1.6.1 VINCRISTINE
11.3.2.1.6.2 BLEOMYCIN
11.3.2.1.6.3 MITOXABNTRONE
11.3.2.1.6.4 ETOPOSIDE
11.3.3 TARGETED DRUG THERAPY
11.3.3.1. IBRUTINIB (IMBRUVICA)
11.3.3.2. BORTEZOMIB (VELCADE)
11.3.3.3. VENETOCLAX (VENCLEXTA)
11.3.3.4. ACALABRUTINIB (CALQUENCE)
11.3.3.5. OTHERS
11.3.4 IMMUNOTHERAPY
11.3.4.1. MONOCLONAL ANTIBODIES
11.3.4.1.1. RITUXIMAB
11.3.4.1.2. OBINUTUZUMAB
11.3.4.1.3. OFATUMUMAB (ARZERRA)
11.3.4.1.4. IBRITUMOMAB TIUXETAN (ZELAVIN)
11.3.4.1.5. TAFASTIMAB (MONJUVI)
11.3.4.1.6. LONCASTUXIMAB TESIRINE (ZYLONTA)
11.3.4.1.7. ALEMTUZUMAB
11.3.4.1.8. BRENTUXIMAB VEDOTIN (ADCETRIS)
11.3.4.1.9. POLATUZUMAB VEDOTIN (POLIVY)
11.3.4.1.10. OTHERS
11.3.4.2. IMMUNE CHECKPOINT INHIBITORS
11.3.4.2.1. PEMBROLIZUMAB (KEYTRUDA)
11.3.4.2.2. OTHERS
11.3.4.3. IMMUNOMODULATING DRUGS
11.3.4.3.1. THALIDOMIDE
11.3.4.3.2. LENALIDOMIDE
11.3.4.4. CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
11.3.4.4.1. AXICABTAGENE CLIOLEUCEL (YESCARTA)
11.3.4.4.2. TISAGENLECLEUCEL (KYMRIAH)
11.3.4.4.3. LISCOBTAGENE MARALEUCEL (BREYANZI)
11.3.4.4.4. BREXUCABTAGENE AUTOLEUCEL (TECRTUS)
12 GLOBAL NON-HODGKIN LYMPHOMA MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 MERGERS & ACQUISITIONS
12.3 NEW PRODUCT DEVELOPMENT & APPROVALS
12.4 EXPANSIONS
12.5 REGULATORY CHANGES
12.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
13 GLOBAL NON-HODGKIN LYMPHOMA MARKET, BY COUNTRY
GLOBAL NON-HODGKIN LYMPHOMA MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
13.2 EUROPE
13.2.1 GERMANY
13.2.2 FRANCE
13.2.3 U.K.
13.2.4 ITALY
13.2.5 SPAIN
13.2.6 RUSSIA
13.2.7 TURKEY
13.2.8 BELGIUM
13.2.9 DENMARK
13.2.10 SWEDEN
13.2.11 POLAND
13.2.12 NORWAY
13.2.13 FINLAND
13.2.14 NETHERLANDS
13.2.15 SWITZERLAND
13.2.16 REST OF EUROPE
13.3 ASIA-PACIFIC
13.3.1 JAPAN
13.3.2 CHINA
13.3.3 SOUTH KOREA
13.3.4 INDIA
13.3.5 AUSTRALIA
13.3.6 SINGAPORE
13.3.7 THAILAND
13.3.8 MALAYSIA
13.3.9 INDONESIA
13.3.10 PHILIPPINES
13.3.11 TAIWAN
13.3.12 INDONESIA
13.3.13 VIETNAM
13.3.14 REST OF ASIA-PACIFIC
13.4 SOUTH AMERICA
13.4.1 BRAZIL
13.4.2 ARGENTINA
13.4.3 REST OF SOUTH AMERICA
13.5 MIDDLE EAST AND AFRICA
13.5.1 SOUTH AFRICA
13.5.2 SAUDI ARABIA
13.5.3 UAE
13.5.4 EGYPT
13.5.5 BAHRAIN
13.5.6 KUWAIT
13.5.7 QATAR
13.5.8 OMAN
13.5.9 ISRAEL
13.5.10 REST OF MIDDLE EAST AND AFRICA
13.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
14 GLOBAL NON-HODGKIN LYMPHOMA MARKET, SWOT AND DBMR ANALYSIS
15 GLOBAL NON-HODGKIN LYMPHOMA MARKET, COMPANY PROFILE
15.1 PFIZER INC.
15.1.1 COMPANY OVERVIEW
15.1.2 REVENUE ANALYSIS
15.1.3 GEOGRAPHIC PRESENCE
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 JANSSEN GLOBAL SERVICES, LLC
15.2.1 COMPANY OVERVIEW
15.2.2 REVENUE ANALYSIS
15.2.3 GEOGRAPHIC PRESENCE
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 ASTRAZENECA
15.3.1 COMPANY OVERVIEW
15.3.2 REVENUE ANALYSIS
15.3.3 GEOGRAPHIC PRESENCE
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 F. HOFFMANN-LA ROCHE LTD
15.4.1 COMPANY OVERVIEW
15.4.2 REVENUE ANALYSIS
15.4.3 GEOGRAPHIC PRESENCE
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.5.1 COMPANY OVERVIEW
15.5.2 REVENUE ANALYSIS
15.5.3 GEOGRAPHIC PRESENCE
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 NOVARTIS
15.6.1 COMPANY OVERVIEW
15.6.2 REVENUE ANALYSIS
15.6.3 GEOGRAPHIC PRESENCE
15.6.4 PRODUCT PORTFOLIO
15.6.5 RECENT DEVELOPMENTS
15.7 SANOFI
15.7.1 COMPANY OVERVIEW
15.7.2 REVENUE ANALYSIS
15.7.3 GEOGRAPHIC PRESENCE
15.7.4 PRODUCT PORTFOLIO
15.7.5 RECENT DEVELOPMENTS
15.8 ELI LILLY & COMPANY
15.8.1 COMPANY OVERVIEW
15.8.2 REVENUE ANALYSIS
15.8.3 GEOGRAPHIC PRESENCE
15.8.4 PRODUCT PORTFOLIO
15.8.5 RECENT DEVELOPMENTS
15.9 BOEHRINGER INGELHEIM
15.9.1 COMPANY OVERVIEW
15.9.2 REVENUE ANALYSIS
15.9.3 GEOGRAPHIC PRESENCE
15.9.4 PRODUCT PORTFOLIO
15.9.5 RECENT DEVELOPMENTS
15.1 TEVA PHARMACEUTICALS
15.10.1 COMPANY OVERVIEW
15.10.2 REVENUE ANALYSIS
15.10.3 GEOGRAPHIC PRESENCE
15.10.4 PRODUCT PORTFOLIO
15.10.5 RECENT DEVELOPMENTS
15.11 SAUDI BIO
15.11.1 COMPANY OVERVIEW
15.11.2 REVENUE ANALYSIS
15.11.3 GEOGRAPHIC PRESENCE
15.11.4 PRODUCT PORTFOLIO
15.11.5 RECENT DEVELOPMENTS
15.12 BRISTOL-MYERS SQUIBB COMPANY
15.12.1 COMPANY OVERVIEW
15.12.2 REVENUE ANALYSIS
15.12.3 GEOGRAPHIC PRESENCE
15.12.4 PRODUCT PORTFOLIO
15.12.5 RECENT DEVELOPMENTS
15.13 MERCK & CO. INC
15.13.1 COMPANY OVERVIEW
15.13.2 REVENUE ANALYSIS
15.13.3 GEOGRAPHIC PRESENCE
15.13.4 PRODUCT PORTFOLIO
15.13.5 RECENT DEVELOPMENTS
15.14 APOTEX CORPORATION
15.14.1 COMPANY OVERVIEW
15.14.2 REVENUE ANALYSIS
15.14.3 GEOGRAPHIC PRESENCE
15.14.4 PRODUCT PORTFOLIO
15.14.5 RECENT DEVELOPMENTS
15.15 AMGEN
15.15.1 COMPANY OVERVIEW
15.15.2 REVENUE ANALYSIS
15.15.3 GEOGRAPHIC PRESENCE
15.15.4 PRODUCT PORTFOLIO
15.15.5 RECENT DEVELOPMENTS
15.16 ABBVIE
15.16.1 COMPANY OVERVIEW
15.16.2 REVENUE ANALYSIS
15.16.3 GEOGRAPHIC PRESENCE
15.16.4 PRODUCT PORTFOLIO
15.16.5 RECENT DEVELOPMENTS
15.17 DR REDDY LABORATORIES
15.17.1 COMPANY OVERVIEW
15.17.2 REVENUE ANALYSIS
15.17.3 GEOGRAPHIC PRESENCE
15.17.4 PRODUCT PORTFOLIO
15.17.5 RECENT DEVELOPMENTS
15.18 SUN PHARMACEUTICALS
15.18.1 COMPANY OVERVIEW
15.18.2 REVENUE ANALYSIS
15.18.3 GEOGRAPHIC PRESENCE
15.18.4 PRODUCT PORTFOLIO
15.18.5 RECENT DEVELOPMENTS
15.19 CASI PHARMACEUTICALS
15.19.1 COMPANY OVERVIEW
15.19.2 REVENUE ANALYSIS
15.19.3 GEOGRAPHIC PRESENCE
15.19.4 PRODUCT PORTFOLIO
15.19.5 RECENT DEVELOPMENTS
15.2 GSK
15.20.1 COMPANY OVERVIEW
15.20.2 REVENUE ANALYSIS
15.20.3 GEOGRAPHIC PRESENCE
15.20.4 PRODUCT PORTFOLIO
15.20.5 RECENT DEVELOPMENTS
15.21 INCYTE PHARMACEUTICALS
15.21.1 COMPANY OVERVIEW
15.21.2 REVENUE ANALYSIS
15.21.3 GEOGRAPHIC PRESENCE
15.21.4 PRODUCT PORTFOLIO
15.21.5 RECENT DEVELOPMENTS
15.22 ADC THERAPEUTICS
15.22.1 COMPANY OVERVIEW
15.22.2 REVENUE ANALYSIS
15.22.3 GEOGRAPHIC PRESENCE
15.22.4 PRODUCT PORTFOLIO
15.22.5 RECENT DEVELOPMENTS
15.23 SEAGEN PHARMACEUTICALS
15.23.1 COMPANY OVERVIEW
15.23.2 REVENUE ANALYSIS
15.23.3 GEOGRAPHIC PRESENCE
15.23.4 PRODUCT PORTFOLIO
15.23.5 RECENT DEVELOPMENTS
15.24 GILEAD SCIENCES
15.24.1 COMPANY OVERVIEW
15.24.2 REVENUE ANALYSIS
15.24.3 GEOGRAPHIC PRESENCE
15.24.4 PRODUCT PORTFOLIO
15.24.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
16 RELATED REPORTS
17 CONCLUSION
18 QUESTIONNAIRE
19 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
